The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sjomkina A.A.

Siberian State Medical University, Tomsk, Russia

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Titova M.A.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk

Mal’tseva A.N.

Federal State Budgetary Educational Establishment of Higher Education 'Kursk State Medical University' of Ministry of Public Health of the Russia, Kursk, Russia

Abadzhyan M.B.

Siberian State Medical University, Tomsk, Russia

Brain-derived neurotrophic factor in multiple sclerosis

Authors:

Sjomkina A.A., Alifirova V.M., Titova M.A., Mal’tseva A.N., Abadzhyan M.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2): 28‑35

DOI: 10.17116/jnevro20191192228

Read: 3349 times

Download PDF (RU)
Contact the author
Table of contents

BRAIN-DERIVED NEUROTROPHIC FACTOR IN MULTIPLE SCLEROSIS
BRAIN-DERIVED NEUROTROPHIC FACTOR IN MULTIPLE SCLEROSIS

To cite this article:

Sjomkina AA, Alifirova VM, Titova MA, Mal’tseva AN, Abadzhyan MB. Brain-derived neurotrophic factor in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2):28‑35. (In Russ.)
https://doi.org/10.17116/jnevro20191192228

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Abstract:

The review presents data on brain-derived neurotrophic factor (BDNF), its structure and functions, the effect on the pathogenesis of experimental autoimmune encephalomyelitis and multiple sclerosis (MS). The correlation of BDNF level with clinical manifestations of MS and the changes of its level during disease-modifying therapy is considered.

Keywords:

brain-derived neurotrophic factor
multiple sclerosis

Authors:

Sjomkina A.A.

Siberian State Medical University, Tomsk, Russia

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Titova M.A.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk

Mal’tseva A.N.

Federal State Budgetary Educational Establishment of Higher Education 'Kursk State Medical University' of Ministry of Public Health of the Russia, Kursk, Russia

Abadzhyan M.B.

Siberian State Medical University, Tomsk, Russia

Close metadata

References:

  1. Shmidt TE. Glatiramer acetate is a first-line drug with a double action for the treatment of remitting multiple sclerosis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2016;8(4):77-80. (In Russ.) https://doi.org/10.14412/2074-2711-2016-4-77-80
  2. Melnikov MV, Pashchenkov MV, Boiko AN. Psychoneuroimmunology and multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(2-2):8-15. (In Russ.) https://doi.org/10.17116/jnevro2015115228-15
  3. Shmidt TE, Yakhno NN. Multiple sclerosis. A guide for physicians. M.: Medpress-inform; 2016. (In Russ.)
  4. Giovannoni G, Tomic D, Bright JR, Havrdová E. «No evident disease activity»: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23(9):1179-1187. https://doi.org/10.1177/1352458517703193
  5. Jönhagen ME. Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord. 2000;14(suppl 1):31-38. https://doi.org/10.1097/00002093-200000001-00006
  6. Robinson RC, Radziejewski C, Spraggon G, Choe S, Greenwald J, Kostura MR, Burtnick LD, Stuart DI, Jones EY. The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site. Protein Sci. 1999;8(12):2589-2597. https://doi.org/10.1110/ps.8.12.2589
  7. Park H, Poo M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013;14(1):7-23. https://doi.org/10.1038/nrn3379
  8. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics. 2007;90(3):397-406. https://doi.org/10.1016/j.ygeno.2007.05.004
  9. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M, Harte RA, Heitner S, Hinrichs AS, Learned K, Lee BT, Li CH, Raney BJ, Rhead B, Rosenbloom KR, Sloan CA, Speir ML, Zweig AS, Haussler D, Kuhn RM, Kent WJ. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 2014;42(Database issue):764-770. https://doi.org/10.1093/nar/gkt1168
  10. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609-642. https://doi.org/10.1146/annurev.biochem.72.121801.161629
  11. Rodriguez-Tébar A, Dechant G, Barde YA. Binding of brain-derived neurotrophic factor to the nerve growth factor receptor. Neuron. 1990;4(4):487-492. https://doi.org/10.1016/0896-6273(90)90107-q
  12. Barker PA. p75NTR is positively promiscuous: novel partners and new insights. Neuron. 2004;42(4):529-533. https://doi.org/10.1016/j.neuron.2004.04.001
  13. Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 1994;263(5153):1618-1623. https://doi.org/10.1126/science.7907431
  14. Tao X, West AE, Chen WG, Corfas G, Greenberg ME. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron. 2002;33(3):383-395. https://doi.org/10.1016/s0896-6273(01)00561-x
  15. Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci. 2009;29(41):12764-12767. https://doi.org/10.1523/jneurosci.3566-09.2009
  16. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung WH, Hempstead BL, Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306(5695):487-491. https://doi.org/10.1126/science.1100135
  17. Matsumoto T, Rauskolb S, Polack M, Klose J, Kolbeck R, Korte M, Barde YA. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci. 2008;11(2):131-133. https://doi.org/10.1038/nn2038
  18. Mashayekhi F, Salehi Z, Jamalzadeh HR. Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis. Acta Medica (Hradec Kralove). 2012;55(2):83-86. https://doi.org/10.14712/18059694.2015.60
  19. Burnouf T, Kuo Y-P, Blum D, Burnouf S, Su C-Y. Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor. Transfusion. 2012;52(8):1721-1728. https://doi.org/10.1111/j.1537-2995.2011.03494.x
  20. Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res. 1996;709(1):122-301. https://doi.org/10.1016/0006-8993(95)01321-0
  21. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26(1):115-123. https://doi.org/10.1016/j.neurobiolaging.2004.03.002
  22. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95(8):2514-2522.
  23. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996;36(2):280-286. https://doi.org/10.1016/0169-328x(95)00250-v
  24. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA, Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010;11(6):763-773. https://doi.org/10.3109/15622971003611319
  25. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010;70(5):289-297. https://doi.org/10.1002/dneu.20758
  26. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry. 2007;62(5):530-535. https://doi.org/10.1016/j.biopsych.2007.01.002
  27. Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther. 2013;5(3):25. https://doi.org/10.1186/alzrt179
  28. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93(6):1412-1421. https://doi.org/10.1111/j.1471-4159.2005.03135.x
  29. Fontenelle LF, Barbosa IG, Luna JV, Rocha NP, Silva Miranda A, Teixeira AL. Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res. 2012;199(3):195-200. https://doi.org/10.1016/j.psychres.2012.03.034
  30. Björkholm C, Monteggia LM. BDNF — a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72-79. https://doi.org/10.1016/j.neuropharm.2015.10.034
  31. Makar TK, Bever CT, Singh IS, Royal W, Trisler D. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol. 2009;210(1-2):40-51. https://doi.org/10.1016/j.jneuroim.2009.02.017
  32. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, Gerhardt E, Neumann H, Sendtner M, Lühder F, Gold R. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain. 2010;133(8):2248-2263. https://doi.org/10.1093/brain/awq179
  33. Herrero-Herranz E, Pardo LA, Gold R, Linker RA. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis. 2008;30(2):162-173. https://doi.org/10.1016/j.nbd.2008.01.001
  34. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol. 2010;225(1):9-17. https://doi.org/10.1016/j.expneurol.2009.11.019
  35. Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, Bharathi BS, Glumm R, Schmitz C, Steinbusch H, Raine CS, Tsokos M, Nitsch R, Zipp F. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol. 2009;66(3):310-322. https://doi.org/10.1002/ana.21719
  36. Javeri S, Rodi M, Tary-Lehmann M, Lehmann PV, Addicks K, Kuerten S. Involvement of brain-derived neurotrophic factor (BDNF) in MP4-induced autoimmune encephalomyelitis. Clin Immunol. 2010;137(2):181-189. https://doi.org/10.1016/j.clim.2010.08.001
  37. Linker R, Lee D-H, Siglienti I, Gold R. Is there a role for neurotrophins in the pathology of multiple sclerosis? J Neurol. 2007;254(1):I33. https://doi.org/10.1007/s00415-007-1007-8
  38. Bayas A, Kruse N, Moriabadi NF, Weber F, Hummel V, Wohleben G, Gold R, Toyka KV, Rieckmann P. Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells. Neurosci Lett. 2003;335(3):155-158. https://doi.org/10.1016/s0304-3940(02)01152-7
  39. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992;358(6382):155-157. https://doi.org/10.1038/358155a0
  40. Schuhmann B, Dietrich A, Sel S, Hahn C, Klingenspor M, Lommatzsch M, Gudermann T, Braun A, Renz H, Nockher WA. A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol. 2005;163(1-2):15-23. https://doi.org/10.1016/j.jneuroim.2005.01.023
  41. Bratke K, Maruschke L, Darowski M, Kuepper M, Braun A, Virchow JC, Lommatzsch M. A role for the neurotrophin receptor TrkB on maturing dendritic cells. J Neuroimmunol. 2007;189(1-2):88-94. https://doi.org/10.1016/j.jneuroim.2007.07.013
  42. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci USA. 1998;95(10):5779-5784. https://doi.org/10.1073/pnas.95.10.5779
  43. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol. 2002; 132(1-2):180-188. https://doi.org/10.1016/s0165-5728(02)00319-3
  44. Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, Tenaglia S, Di Filippo M, Calabresi P. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler. 2007;13(3):313-331. https://doi.org/10.1177/1352458506070146
  45. Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol. 2003;57(5):493-497. https://doi.org/10.1046/j.1365-3083.2003.01260.x
  46. Petereit HF, Lindemann H, Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler. 2003;9(1):16-20. https://doi.org/10.1191/1352458503ms869oa
  47. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol. 2005;62(2):176-182. https://doi.org/10.1111/j.1365-3083.2005.01649.x
  48. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125(1):75-85. https://doi.org/10.1093/brain/awf015
  49. Lisak RP, Benjamins JA, Bealmear B, Yao B, Land S, Nedelkoska L, Skundric D. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures. Mult Scler. 2006;12(2):149-168. https://doi.org/10.1191/135248506ms1251oa
  50. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Yao B, Land S, Studzinski D. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation. 2007;4:30. https://doi.org/10.1186/1742-2094-4-30
  51. Tsakiri A, Ravanidis S, Lagoudaki R, Poulatsidou KN, Svane IM, Frederiksen JL, Grigoriadis N. Neuroprotective and anti-inflammatory mechanisms are activated early in optic neuritis. Acta Neurol Scand. 2015;131(5):305-312. https://doi.org/10.1111/ane.12344
  52. Patanella AK, Zinno M, Quaranta D, Nociti V, Frisullo G, Gainotti G, Tonali PA, Batocchi AP, Marra C. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res. 2010;88(5):1106-1112. https://doi.org/10.1002/jnr.22276
  53. Prokopova B, Hlavacova N, Vlcek M, Penesova A, Grunnerova L, Garafova A, Turcani P, Kollar B, Jezova D. Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis. J Neuroimmunol. 2017;302:34-40. https://doi.org/10.1016/j.jneuroim.2016.11.007
  54. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1998;92(1-2):113-121. https://doi.org/10.1016/s0165-5728(98)00191-x
  55. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56(6):702-708. https://doi.org/10.1212/wnl.56.6.702
  56. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler. 2001;7(4):209-219. https://doi.org/10.1177/135245850100700401
  57. Peresedova AV, Zavalishin IA, Adarcheva LS, Askarova LSh, Zakharova MN, Eliseeva DD, Niyazbekova AS, Stoida NI, Trifonova OV. Glatiramer acetate (Copaxone) in the treatment of multiple sclerosis. Results of long-term use: emerging issues and directions for further research. Nervnye Bolezni. 2012;4:26-30. (In Russ.)
  58. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(8 suppl 4):3-9. https://doi.org/10.1212/wnl.58.8_suppl_4.s3
  59. Ziemssen T, Kümpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002;125(11):2381-2391. https://doi.org/10.1093/brain/awf252
  60. Blanco Y, Moral EA, Costa M, Gómez-Choco M, Torres-Peraza JF, Alonso-Magdalena L, Alberch J, Jaraquemada D, Arbizu T, Graus F, Saiz A. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett. 2006;406(3):270-275. https://doi.org/10.1016/j.neulet.2006.07.043
  61. Kasatkin DS. Place of first-line drugs in the treatment of multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(12):145-151. (In Russ.) https://doi.org/10.17116/jnevro2016116121145-151
  62. Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol. 2008;197(2):147-151. https://doi.org/10.1016/j.jneuroim.2008.04.033
  63. Azoulay D, Mausner-Fainberg K, Urshansky N, Fahoum F, Karni A. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol. 2009;211(1-2):114-119. https://doi.org/10.1016/j.jneuroim.2009.04.004
  64. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol. 2006;118(1):77-82. https://doi.org/10.1016/j.clim.2005.09.005
  65. Boutros T, Croze E, Yong VW. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J Neurochem. 1997;69(3):939-946. https://doi.org/10.1046/j.1471-4159.1997.69030939.x
  66. Yoshimura S, Ochi H, Isobe N, Matsushita T, Motomura K, Matsuoka T, Minohara M, Kira J. Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. Mult Scler. 2010;16(10):1178-1188. https://doi.org/10.1177/1352458510375706
  67. Lindquist S, Hassinger S, Lindquist JA, Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult Scler. 2011;17(7):851-866. https://doi.org/10.1177/1352458511399797
  68. Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012;180(1):267-274. https://doi.org/10.1016/j.ajpath.2011.09.037
  69. Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;251(1-2):14-24. https://doi.org/10.1016/j.jneuroim.2012.06.005
  70. Zakharova MN, Abramova AA, Askarova LSh, Bakulin IS, Bryukhov VV, Vasil’ev AV, Eliseeva DD, Zakroishchikova IV, Ivanova MV, Korzhova YuE, Kochergin IA, Krotenkova IA, Krotenkova MV, Lysogorskaya EV, Polekhina NV, Roslyakova AA, Simaniv TO, Surniina ZV, Teunova MKh, Shchepareva ME. Rasseyannyi Skleroz: Voprosy Diagnostiki i Lecheniya. M.: Media Mente; 2018. (In Russ.)
  71. Văcăraş V, Major ZZ, Buzoianu AD. Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report. Neurol Neurochir Pol. 2017;51(3):221-226. https://doi.org/10.1016/j.pjnns.2017.03.002
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.